Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29841160 | 0.81 | PTGER4 (0.35) | KMT2ALMNAMAPTPOLBPTGER4 | |
| SCHEMBL18555054 | 0.81 | PTGER4 (0.35) | KMT2ALMNAMAPTPOLBPTGER4 | |
| SCHEMBL18555083 | 0.79 | HSD17B10 (0.43) | LMNAPTGER4ALOX15TSHRKDM4E | |
| SCHEMBL31584632 | 0.77 | CYP2C19 (0.49) | MEN1KMT2APOLBL3MBTL1TSHR | |
| SCHEMBL18611010 | 0.75 | LMNA (0.53) | MEN1KMT2ALMNAMAPTPOLB | |
| SCHEMBL29355625 | 0.75 | LMNA (0.53) | MEN1KMT2ALMNAMAPTPOLB | |
| SCHEMBL29357130 | 0.74 | LMNA (0.52) | MEN1KMT2ALMNAMAPTPOLB | |
| SCHEMBL11628584 | 0.71 | CNR1 (0.43) | MEN1KMT2ALMNAMAPTPOLB | |
| SCHEMBL31140078 | 0.70 | PTGER4 (0.37) | MEN1KMT2AMAPTPOLBPTGER4 | |
| SCHEMBL19236960 | 0.70 | MEN1 (0.46) | MEN1KMT2ALMNAMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | CFD, F12, F3 | MEN1 326/4885KMT2A 3874/4885LMNA 1125/4885 |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | MEN1 306/4885KMT2A 3835/4885LMNA 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.